diabetes glp-1 agonist Trends in the Development of Receptor Agonists GLP-1 Receptor Agonists and Research

If patient cannot tolerate 3 mg dose, 2.4 mg dose may be used

Notably, nearly 50% of the retatrutide phase 2 obesity trial were men, which is higher than in phase 3 clinical trials with tirzepatide (32.5% in SURMOUNT-1 [27]) and semaglutide 2.4 mg (25.9% in STEP-1 [8])

Anti-obesity drug discovery: advances and challenges

During dulaglutide shortages, it is important to consider the pharmacokinetic and pharmacodynamic differences among GLP-1 receptor agonists

Over the last several years, GLP-1 prescriptions have surged because these drugs are widely discussed not only for diabetes control but also for weight loss and long-term chronic weight management, including use patterns that expanded public awareness and demand